Science Technology

ALGENEX selected to present at the Animal Health Investment Innovation Showcase

Mar 22 2019

Animal Health Investment Europe is a premier international investment forum. The event was held on February 26th and 27th in London. More than 60 companies applied to participate in the Showcase, but only 24 were finalists, among whom was ALGENEX.

The finalists, hand-picked by the Selection Committee, introduced themselves and their products/services on the main stage, in a quick-fire round of presentations.

Claudia Jiménez, General Manager of ALGENEX, explained the CrisBio® technology, which consists in natural bio-reactors which have unique advantages for industrial production of any kind of recombinant protein, offering the most simple, cost-effective and scalable production technology up to date. CrisBio® has multiple advantages to obtain biotechnological high-tech products, with respect to classical production based on bioreactors.

 

Related links

Animal Health Event

CrisBio® technology

Science Technology

ALGENEX appoints new Strategic Advisory Board (SAB)

Mar 13 2019

Advisors include recognized industry leaders in international healthcare as Dr. René Aerts, Jean Stéphenne and Dr. Claudia D´Augusta.

ALGENEX SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, today announces the formation of its Strategic Advisory Board (SAB). The newly-formed SAB will work closely with ALGENEX’s management team to further advance its progress in the animal health industry and support the company’s move into human health. The SAB will also guide the company’s expansion and development of its own product portfolio. Dr. René Aerts, Jean Stéphenne and Dr. Claudia D´Augusta will join the SAB.

“We are proud to welcome such well-recognized industry leaders to our newly formed Strategic Advisory Board,” said José M. Escribano, CSO of ALGENEX. “Their commitment to the company is a clear validation of the strength and potential impact of our technologies and their combined experience will be a great asset as we work to make ALGENEX the preferred partner for companies whose business requires efficient, robust and scalable protein expression systems.”

Dr. René Aerts is the founder of RA Consultancy, supporting top tier Animal Health companies in M&A, R&D and manufacturing strategy. He retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previously held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International.

Jean Stéphenne is a highly-experienced life sciences executive who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies. He was Chairman of TiGenix until its acquisition by Takeda in 2018 and previously served as a member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals(now GSK Vaccines).

Dr. Claudia D’Augusta currently serves as CFO of the Swiss biotechnology company Therachon and as venture partner at Ysios Capital Partners in Spain. Prior to this she was as CFO at TiGenix, where she led the company through its merger with Cellerix, the approval of its stem cell therapy product Alofisel, its Nasdaq IPO and finally its €520M acquisition by Takeda.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex´ first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company Science Technology

ALGENEX closes funding round and strengthens team with key senior manager appointments

Mar 05 2019

ALGENEX SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, today announces that it has closed a financing round of circa €4M and completed its executive team with the appointment of Claudia Jimenez as General Manager and Virginia Gonzalez as Chief Financial Officer.

The new funds will allow the scale up of ALGENEX’ proprietary CrisBio® baculovirus-expression platform ahead of an anticipated submission to the European Medicines Agency (EMA) of a
CrisBio®-based minor species vaccine. CrisBio® is a versatile, reduced-cost and scalable insect- based protein production system that delivers unprecedented productivity – up to 20x more per volume unit than insect cells cultured in bioreactors.

The funds will also support the further commercial roll out of ALGENEX’ TopBac® system, a plug and play patented technology that significantly increases the productivity of existing baculovirus systems.

The financing was led by Cleon Capital and Vita Advisory and was funded primarily by high net worth individuals, many of whom are notable biotech investors and experienced executives. Existing investors also participated in the round.

“We were impressed by the scientific accomplishments of ALGENEX in their initial years of development. The robustness of their technologies and potential to positively disrupt the way vaccines and other recombinant biologics are being produced convinced us to support the company’s growth strategy,” said Nicola Zambón, founder and partner at Cleon Capital.

“ALGENEX’ technologies have the potential to revolutionize the vaccine industry, and more broadly the production of biologics. The applications include vaccines in the animal health space – the current focus – and extend to faster and cheaper production of human health vaccines in emerging geographies, allowing a rapid response to epidemics. We are very excited about supporting the company’s expansion,” said Roberto Barzi, Managing Partner at Vita.

ALGENEX also announces today key senior appointments to its management team. Claudia Jiménez has been appointed as General Manager and Virginia González as Chief Financial Officer. José M. Escribano, founder and until recently Scientific Advisor to the company, has joined ALGENEX on a permanent basis as Chief Scientific Officer. Romy M. Dalton, who was previously operations manager, will take up the position of Chief Operations Officer.

“I am delighted to join ALGENEX at this exciting time for the company,” said Claudia Jiménez, General Manager. “ALGENEX has the potential to be a game-changer in protein manufacturing and I look forward to working with the highly skilled management team to deliver on our goals. Together with the support of our new and existing investors, we are in a good position to make ALGENEX the preferred partner for companies whose business requires efficient, robust and scalable protein expression systems.”

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex´ first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company CrisBio Science Technology

BIOKIT licenses CRISBIO™ technology to make high quality recombinant proteins for in vitro diagnostics for human use

Mar 29 2017

BIOKIT and ALGENEX are extending their non-exclusive, commercial license agreement, to include also the CRISBIO™ technology for the manufacturing of recombinant proteins.

CRISBIO™ is the next generation technology in the development and manufacturing of recombinant proteins which ALGENEX developed in its laboratories in Madrid. Whereas TopBac® is the booster for the BEV-based protein synthesis in insect cells, CRISBIO™ is the production vehicle, it is the technology to use TopBac® in insects as living bioreactors in a fully automated way. The quality and the productivity are unprecedented. The development times can be as short as 2 months from gene sequence to obtaining a purified protein. CRISBIO™ is used for diagnostics, animal health vaccines, biosimilars to name a few.

“After the successful implementation and scaling up of the IBES® technology we are very happy to be the first CRISBIO™ licensee in our field. ALGENEX never stopped improving BEV-based technologies. Using new economical approaches such as CRISBIO™ in developing and producing innovative and high quality diagnostic kits and raw materials is our way to confirm our leadership position. Recombinant proteins are a given in our business, many new technologies are offered indeed, but few combine good quality with good economics. ALGENEX does.” says Dr Pau Bruguera, Senior Vice-President R&D for Biokit.

“It goes without saying that this first commercial license for CRISBIO™ to a partner like BIOKIT is for ALGENEX a milestone. It is a major validation of its capacity to develop and deliver difficult to produce proteins in a short period of time to a demanding market from a quality, from a production flexibility and from a cost-of-goods point of view.” says Dr. Jose Escribano, founder and scientific advisor for ALGENEX.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex´ first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com.

About Biokit

Biokit is a Spanish company which develops and manufactures in vitro diagnostics kits for the detection of infectious diseases, coagulation disorders, and others. Using various immunoassay formats, from manual, rapid agglutination tests, to fully- automated, high-sensitivity magnetic-particle-based chemiluminescent systems,
Biokit has developed a broad portfolio of products that are distributed, either under its own brand name or under the brand name of the most important diagnostics
companies worldwide. The use of recombinant or native proteins, antigens and antibodies, developed and/or purified using last-generation technologies by the internal Biotechnology department guarantees the optimal control of the raw materials which is the basis for the outstanding performance of the assays. The company was created in 1973 and it is part of Werfen, the international group headquartered in Barcelona.

For more information, please visit Biokit.com.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company CrisBio Science Technology

ALGENEX has signed its first commercial license agreement with FATRO

Sep 08 2015

ALGENEX S.L. announced today that it has signed its first commercial license agreement with the Italian animal health vaccines company FATRO S.p.A. for the worldwide use and industrial production of a recombinant vaccine with CrisBioTM technology.

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex´ first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com